iBio preliminary FY2023 net loss $29-29.5M; cash drops to $7.6M; warrants repriced to $0.50

iBio, Inc.

2023-FY EPS reported -$5.31

Preliminary FY2023 net loss from continuing ops expected $29.0M-$29.5M vs $29.6M prior year.
Cash at June 30, 2023: $7.6M (incl $3.3M restricted) down from $28.7M (incl $6M) year ago.
Common shares outstanding increased to ~22.4M from 8.7M year ago.
Term note principal balance reduced to ~$13.1M from $22.4M.
Amended exercise price of Series A and B warrants (covering ~5.5M shares) to $0.50 from $1.04.

item 1.01 item 2.02 item 3.03

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

iBio, Inc. reported twelve months ending June 30, 2023 results: net income net loss from continuing operations ... to be between $29.0 million and $29.5 million.

Period: twelve months ending June 30, 2023
Net income: net loss from continuing operations ... to be between $29.0 million and $29.5 million
Result: preliminary results

Exact text from the filing

On a preliminary unaudited basis, the Company expects net loss from continuing operations for the twelve months ending June 30, 2023, to be between $29.0 million and $29.5 million

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-088326

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.